P. 01

TRANSACTION REPORT

OCT-17-2002 THU 01:58 PM

*	FOR: AMGEN LEGAL	805 4998011		
*	DATE START RECEIVER	TX TIME PAGES TYPE	NOTE	M# DP
X	OCT-17 01:54 PM 17037465328	3'22" 9 SEND	OK	171

TOTAL:

3M 22S PAGES:

9

AMGEN INC.

One Amgen Center Drive Thousand Oaks, CA 91320 (805) 447-1000

LAW DEPARTMENT

FAX Number:

(805) 499-8011

TO:

Examiner Robert Hayes

Group Art Unit: 1647

U.S. Patent and Trademark Office

Phone: (703) 305-3132 Fax No.: (703) 746-5328

FROM:

Robert Sharp

Direct No.: (805) 447-5992

DATE:

October 17, 2002

RE:

USSN: 08/182,183

Filed: May 23, 1994

GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR

Our Docket No.: SYNE-225E

AMGEN INC.

One Amgen Center Drive Thousand Oaks, CA 91320 (805) 447-1000

LAW DEPARTMENT

FAX Number:

(805) 499-8011

Examiner Robert Hayes

Group Art Unit: 1647

U.S. Patent and Trademark Office

Phone: (703) 305-3132 Fax No.: (703) 746-5328

FROM:

Robert Sharp

Direct No.: (805) 447-5992

DATE:

October 17, 2002

RE:

USSN: 08/182,183

Filed: May 23, 1994

GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR

Our Docket No.: SYNE-225E

There are a total of 9 pages being transmitted. If all of the pages are not received, please Robert Sharp at (805) 447-5992.

COMMENTS:

Enclosed is a Supplemental Amendment totaling 8 pages on the above referenced patent application.

Please confirm receipt of this Amendment by return facsimile or telephone call. Thank you for your consideration.

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

Signature